Urinary Tract Infection Treatment Market 2026: Current Trends, Research Analysis By Leading Players- Cipla, Johnson & Johnson, Bayer AG, Pfizer, GlaxoSmithKline, Boehringer Ingelheim

Urinary Tract Infection (UTI) is caused when bacteria enters the urethra and infects the urinary bladder, causing severe health issues. UTI infections are common health problems in females than in males with biologic factors accounting as the major cause. Antibiotics are usually the first line of treatment prescribed by doctors for urinary tract infections. According to the site of manifestation by the microbe, infections are classified as cystitis (bladder), urethritis (urethra), prostatitis (prostate) or pyelonephritis (kidney). Painful and increased frequency of urination, excessive and involuntary passing of urine at night are the common symptoms associated with UTI. Hospitalized patients using urinary catheters are at a higher risk for developing UTI.

Approval of combination products for improving indications of existing drugs and to combat multi-drug resistant bacteria are some key factors positively affecting market growth. For instance, in 2015, FDA approved Avycaz (ceftazidime and avibactam) for complicated abdominal and urinary tract infections in combination with metronidazole that has limited or no alternative treatment options.

Get a Sample Copy Of This Research Report : www.coherentmarketinsights.com/insight/request-sample/1178

Increasing prevalence of recurring urinary infections is expected to boost growth of the urinary tract infection treatment market
Rise in chronic kidney diseases and increasing use of urinary catheterization is leading to development of urinary infections and this is expected to be major growth drivers for urinary tract infection market. According to the Centers of Disease Control and Prevention, 2016, UTIs are the most common bacterial infections globally, affecting 150 million people every year. Furthermore, about 10 in 25 women and 3 in 25 men are estimated to have symptoms of at least one UTI during their lifetime. According to the study by Sultan Qaboos University Medical Journal, 2013, around 50–60% of women report at least one UTI in their lifetime, and one in three will have at least one symptomatic UTI necessitating antibiotic treatment by age 24.

Strategic collaborations is the strategy adopted by key players in the market to enhance its presence and for new drug development
Strategy of leading players is to achieve growth through mergers & acquisitions and collaborations. In 2016, GlaxoSmithKline and Fimbrion Therapeutics, Inc., entered into a collaboration, which is focused on preclinical development of mannose-containing small molecule compounds called mannosides for the treatment and prevention of urinary tract infections.

Key players operating in the urinary tract infection treatment market include Cipla Ltd., Johnson & Johnson, Bayer AG, Pfizer Inc., GlaxoSmithKline, Boehringer Ingelheim, F. Hoffmann-La Roche Ltd., Novartis AG AstraZeneca Plc, and Roche Ltd.

Download The PDF Brochure: www.coherentmarketinsights.com/insight/request-pdf/1178

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

This release was published on openPR.